Project owner(s): European Foundation for the Study of Chronic Liver Failure
Project's time span: 2019 - 2024
The MICROB-PREDICT project is a comprehensive pan-European research initiative that integrates microbiome and other patient data from large-scale studies to create a vast database. It involves over 200,000 data points from around 10,000 subjects, including various biological samples collected longitudinally. The project aims to identify and validate microbiome-based biomarkers for healthy conditions, decompensated cirrhosis, progression to acute-on-chronic liver failure (ACLF), and treatment response. It also considers the impact of environmental factors, lifestyle choices, comorbidities, aging, geographic, and socio-economic differences.
The project's goal is to translate this knowledge into practical tools for clinical and patient use, including point-of-care diagnostic tests and advanced nanobiosensors for smartphone-based self-monitoring. A key focus is on determining biomarker signatures to predict responses to human albumin treatment in a clinical trial. Spanning six years, MICROB-PREDICT aims to shift from symptom-based to factual and guided treatment, developing personalized and efficient treatment methods to ease patient and healthcare system burdens. The contribution of the research group is to do a cost benefit analysis of the interventions. The results are not available yet. Link to the webpage.
Publications:
- Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis. Hepatology. 2020. Link to publication.